1068977-12-7

Basic information

• Product Name: 2-(2-methoxyphenyl)-5-pyrimidinecarboxylic acid
• Synonyms: 2-(2-methoxyphenyl)-5-pyrimidinecarboxylic acid;2-(2-Methoxyphenyl)pyrimidine-5-carboxylic acid
• CAS NO: 1068977-12-7
• Molecular Formula: C₁₂H₁₀N₂O₃
• Molecular Weight: 230.2194
• Mol File: 1068977-12-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(2-methoxyphenyl)-5-pyrimidinecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-methoxyphenyl)-5-pyrimidinecarboxylic acid(1068977-12-7)
• EPA Substance Registry System: 2-(2-methoxyphenyl)-5-pyrimidinecarboxylic acid(1068977-12-7)

Safety Data

• Hazardous Substances Data: 1068977-12-7(Hazardous Substances Data)

Usage

Compound type

Pyrimidinecarboxylic acid derivative

Substituent group

Methoxyphenyl group

Position of substituent group

Attached to the 2-position of the pyrimidine ring

Structural similarity

Nucleobases

Potential applications

Pharmaceutical (as a drug or drug precursor)

Current status

Pharmacological properties under investigation

Ability

Interact with biological systems

Upstream product

• 5720-06-9 2-Methoxyphenylboronic acid 
• 374068-01-6 2-bromopyrimidine-5-carboxylic acid 

Relevant articles and documents

Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models

Activation of prostanoid EP2 receptor exacerbates neuroinflammatory and neurodegenerative pathology in central nervous system diseases such as epilepsy, Alzheimer's disease, and cerebral aneurysms. A selective and brain-permeable EP2 antagonist will be useful to attenuate the inflammatory consequences of EP2 activation and to reduce the severity of these chronic diseases. We recently developed a brain-permeable EP2 antagonist 1 (TG6-10-1), which displayed anti-inflammatory and neuroprotective actions in rodent models of status epilepticus. However, this compound exhibited moderate selectivity to EP2, a short plasma half-life in rodents (1.7 h) and low aqueous solubility (27 μM), limiting its use in animal models of chronic disease. With lead-optimization studies, we have developed several novel EP2 antagonists with improved water solubility, brain penetration, high EP2 potency, and selectivity. These novel inhibitors suppress inflammatory gene expression induced by EP2 receptor activation in a microglial cell line, reinforcing the use of EP2 antagonists as anti-inflammatory agents.

PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS

This invention is directed to a compound wherein R1, R2, R3, R4 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or